Search

Your search keyword '"Collini, Valentino"' showing total 30 results
Start Over Author "Collini, Valentino"
30 results on '"Collini, Valentino"'

1. Update on the diagnosis and treatment of pericardial diseases: a position paper of the Italian Society of Cardiology in collaboration with the study group on cardiomyopathies and pericardial diseases

Author

Imazio, Massimo, Collini, Valentino, Aimo, Alberto, Autore, Camillo, Bauce, Barbara, Biagini, Elena, Cappelli, Francesco, Castelletti, Silvia, D’Ascenzi, Flavio, De Gregorio, Cesare, Limongelli, Giuseppe, Marzo, Francesca, Merlo, Marco, Musumeci, Beatrice, Paolillo, Stefania, Tini, Giacomo, Pedrinelli, Roberto, Filardi, Pasquale Perrone, and Sinagra, Gianfranco

Published
2024
Full Text
View/download PDF

2. Update on the diagnosis and treatment of pericardial diseases: a position paper of the Italian Society of Cardiology in collaboration with the study group on cardiomyopathies and pericardial diseases

Author

Imazio, Massimo, Collini, Valentino, Aimo, Alberto, Autore, Camillo, Bauce, Barbara, Biagini, Elena, Cappelli, Francesco, Castelletti, Silvia, D’Ascenzi, Flavio, De Gregorio, Cesare, Limongelli, Giuseppe, Marzo, Francesca, Merlo, Marco, Musumeci, Beatrice, Paolillo, Stefania, Tini, Giacomo, Pedrinelli, Roberto, Filardi, Pasquale Perrone, and Sinagra, Gianfranco

Published
2025
Full Text
View/download PDF

3. Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype

Author

Toma, Matteo, Savonitto, Giulio, Lombardi, Carlo Maria, Airò, Edoardo, Driussi, Mauro, Gentile, Piero, Howard, Luke, Moschella, Martina, Di Poi, Emma, Pagnesi, Matteo, Monti, Simonetta, Collini, Valentino, D’Angelo, Luciana, Vecchiato, Veronica, Giannoni, Alberto, Adamo, Marianna, Barbisan, Davide, Bauleo, Carolina, Garascia, Andrea, Metra, Marco, Sinagra, Gianfranco, Giudice, Francesco Lo, Stolfo, Davide, and Ameri, Pietro

Published
2024
Full Text
View/download PDF

7. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension

Author

Stolfo, Davide, Barbisan, Davide, Ameri, Pietro, Lombardi, Carlo Mario, Monti, Simonetta, Driussi, Mauro, Zovatto, Isabella Carlotta, Gentile, Piero, Howard, Luke, Toma, Matteo, Pagnesi, Matteo, Collini, Valentino, Bauleo, Carolina, Guglielmi, Giulia, Adamo, Marianna, D'Angelo, Luciana, Nalli, Chiara, Sciarrone, Paolo, Moschella, Martina, Zorzi, Barbara, Vecchiato, Veronica, Milani, Martina, Di Poi, Emma, Airò, Edoardo, Metra, Marco, Garascia, Andrea, Sinagra, Gianfranco, and Lo Giudice, Francesco

Published
2023
Full Text
View/download PDF

9. Recurrent pericarditis in older adults: Clinical and laboratory features and outcome.

Author

Bizzi, Emanuele, Cavaleri, Francesco, Mascolo, Ruggiero, Conte, Edoardo, Maggiolini, Stefano, Decarlini, Caterina Chiara, Maestroni, Silvia, Collini, Valentino, Sicignano, Ludovico Luca, Verrecchia, Elena, Manna, Raffaele, Pancrazi, Massimo, Trotta, Lucia, Lopalco, Giuseppe, Malandrino, Danilo, Pallini, Giada, Catenazzi, Sara, Carrozzo, Luisa, Emmi, Giacomo, and Lazaros, George

Subjects
THERAPEUTIC use of proteins, PLEURAL effusions, PERICARDIAL effusion, LEUKOCYTE count, NONSTEROIDAL anti-inflammatory agents, ADRENOCORTICAL hormones, PERICARDIUM paracentesis, PERICARDITIS, TREATMENT effectiveness, RETROSPECTIVE studies, TERTIARY care, DESCRIPTIVE statistics, FEVER, COLCHICINE, LONGITUDINAL method, RESEARCH, MEDICAL records, ACQUISITION of data, PAIN, DISEASE relapse, DYSPNEA, COMORBIDITY, SYMPTOMS, OLD age
Abstract

Background: Current guidelines for the diagnosis and treatment of pericarditis refer to the general adult population. Few and fragmentary data regarding recurrent pericarditis in older adults exist. Objective of the Study: Given the absence of specific data in scientific literature, we hypothesized that there might be clinical, laboratory and outcome differences between young adults and older adults affected by idiopathic recurrent pericarditis. Materials and Methods: We performed an international multicentric retrospective cohort study analyzing data from patients affected by recurrent pericarditis (idiopathic or post‐cardiac injury) and referring to tertiary referral centers. Clinical, laboratory, and outcome data were compared between patients younger than 65 years (controls) and patients aged 65 or older. Results: One hundred and thirty‐three older adults and 142 young adult controls were enrolled. Comorbidities, including chronic kidney diseases, atrial fibrillation, and diabetes, were more present in older adults. The presenting symptom was dyspnea in 54.1% of the older adults versus 10.6% in controls (p < 0.001); pain in 32.3% of the older adults versus 80.3% of the controls (p < 0.001). Fever higher than 38°C was present in 33.8% versus 53.5% (p = 0.001). Pleural effusion was more prevalent in the older adults (55.6% vs 34.5%, p < 0.001), as well as severe pericardial effusion (>20 mm) (24.1% vs 12.7%, p = 0.016) and pericardiocentesis (16.5% vs 8.5%, p = 0.042). Blood leukocyte counts were significantly lower in the older adults (mean + SE: 10,227 + 289/mm3 vs 11,208 + 285/mm3, p = 0.016). Concerning therapies, NSAIDS were used in 63.9% of the older adults versus 80.3% in the younger (p = 0.003), colchicine in 76.7% versus 87.3% (p = 0.023), corticosteroids in 49.6% versus 26.8% (p < 0.001), and anakinra in 14.3% versus 23.9% (p = 0.044). Conclusions: Older adults affected by recurrent pericarditis show a different clinical pattern, with more frequent dyspnea, pleural effusion, severe pericardial effusion, and lower fever and lower leukocyte count, making the diagnosis sometimes challenging. They received significantly less NSAIDs and colchicine, likely due to comorbidities; they were also treated less commonly with anti‐IL1 agents, and more frequently with corticosteroids. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. The impact of the European Society of Cardiology guidelines and whole exome sequencing on genetic testing in hereditary cardiac diseases

Author

Mio, Catia, primary, Zucco, Jessica, additional, Fabbro, Dora, additional, Bregant, Elisa, additional, Baldan, Federica, additional, Allegri, Lorenzo, additional, D'Elia, Angela Valentina, additional, Collini, Valentino, additional, Imazio, Massimo, additional, Damante, Giuseppe, additional, and Faletra, Flavio, additional

Published
2024
Full Text
View/download PDF

11. Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension.

Author

Savonitto, Giulio, Barbisan, Davide, Ameri, Pietro, Lombardi, Carlo Maria, Monti, Simonetta, Driussi, Mauro, Gentile, Piero, Howard, Luke, Toma, Matteo, Pagnesi, Matteo, Collini, Valentino, Bauleo, Carolina, Adamo, Marianna, D'Angelo, Luciana, Nalli, Chiara, Giannoni, Alberto, Vecchiato, Veronica, Di Poi, Emma, Airo, Edoardo, and Metra, Marco

Subjects
PULMONARY arterial hypertension, PULMONARY hypertension, DIURETICS, HEART failure, PROGNOSIS
Abstract

Aims: The use of loop diuretics in pulmonary arterial hypertension (PAH) is less frequent compared with heart failure. The clinical and prognostic characteristics of PAH patients according to loop diuretic use remain unexplored. In this study, we retrospectively analysed the characteristics and survival of PAH patients requiring different doses of loop diuretics. Methods and results: Patients diagnosed with PAH between 2001 and 2022 at seven European centres for the management of PAH. According to the median equivalent dose of furosemide in the overall cohort, patients were divided into two subgroups: no/low‐dose loop diuretic and high‐dose loop diuretic. Primary outcome was 5 year all‐cause mortality. Among the 397 patients included, 227 (57%) were treated with loop diuretics. Median daily furosemide equivalent dose was 25 mg, and accordingly patients were divided in no/low dose (i.e. ≤25 mg, n = 257, 65%) vs. high dose (i.e. >25 mg, n = 140, 35%). Patients in the high‐dose group were older, more likely to have comorbidities, and had a more severe disease according to the ESC/ERS risk category. Crude 5 year survival was significantly shorter in patients in the high‐dose group, but after adjustment for age, sex, and risk category, high loop diuretic dose was not significantly associated with the primary outcome. Conclusions: Use of high dose of loop diuretics in PAH is associated with a higher burden of comorbidities, more severe disease, and worse survival. However, in PAH, the need of high loop diuretic dose is a marker of disease severity and not an independent prognostic factor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis

Author

Collini, Valentino, primary, Andreis, Alessandro, additional, De Biasio, Marzia, additional, De Martino, Maria, additional, Isola, Miriam, additional, Croatto, Nicole, additional, Lepre, Veronica, additional, Cantarini, Luca, additional, Merlo, Marco, additional, Sinagra, Gianfranco, additional, Abbate, Antonio, additional, Lazaros, George, additional, Brucato, Antonio, additional, Klein, Allan L, additional, and Imazio, Massimo, additional

Published
2024
Full Text
View/download PDF

15. Efficacy and safety of colchicine for the treatment of myopericarditis

Author

Collini, Valentino, primary, De Martino, Maria, additional, Andreis, Alessandro, additional, De Biasio, Marzia, additional, Gaspard, Francesca, additional, Paneva, Elena, additional, Tomat, Mariacristina, additional, Deferrari, Gaetano Maria, additional, Isola, Miriam, additional, and Imazio, Massimo, additional

Published
2024
Full Text
View/download PDF

18. 152 PERFORMANCE OF RISK STRATIFICATION SCORES AND ROLE OF COMORBIDITIES IN OLDER VS YOUNGER PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Author

Stolfo, Davide, primary, Barbisan, Davide, additional, Ameri, Pietro, additional, Lombardi, Carlo Mario, additional, Monti, Simonetta, additional, Driussi, Mauro, additional, Zovatto, Isabella Carlotta, additional, Gentile, Piero, additional, Howard, Luke, additional, Toma, Matteo, additional, Pagnesi, Matteo, additional, Collini, Valentino, additional, Bauleo, Carolina, additional, Guglielmi, Giulia, additional, Adamo, Marianna, additional, D´angelo, Luciana, additional, Nalli, Chiara, additional, Sciarrone, Paolo, additional, Moschella, Martina, additional, Zorzi, Barbara, additional, Vecchiato, Veronica, additional, Milani, Martina, additional, Poi, Emma Di, additional, Airò, Edoardo, additional, Metra, Marco, additional, Garascia, Andrea, additional, Sinagra, Gianfranco, additional, and Giudice, Francesco Lo, additional

Published
2022
Full Text
View/download PDF

22. Coronavirus disease 2019 vaccination-related pericarditis: a single tertiary-center experience

Author

Collini, Valentino, Imazio, Massimo, De Biasio, Marzia, Sinagra, Gianfranco, Collini, Valentino, Imazio, Massimo, De Biasio, Marzia, and Sinagra, Gianfranco

Subjects
Male, COVID-19 Vaccines, SARS-CoV-2, Vaccination, COVID-19, General Medicine, Myocarditis, Humans, Pericarditis, Female, Cardiology and Cardiovascular Medicine, Pandemics
Abstract

Aims: Vaccination represents a cornerstone of prevention in the COVID-19 pandemic. Rare adverse events including acute pericarditis and myopericarditis have been reported. Methods: All consecutive patients referred to our referral center for pericardial diseases following COVID-19 vaccination from 1 April 2021 to 15 April 2022 were included. Acute pericarditis and myopericarditis were diagnosed according to ESC guidelines. Patients with SARS-CoV-2 infection were excluded from the study. Results: Twenty-four patients (79% men) aged 39.7 ± 19.8 years were referred to our center with pericarditis after receiving COVID-19 vaccination. Thirteen (54%) patients were diagnosed with myopericarditis. The mean time between vaccination and symptoms onset was 7.0 ± 4.9 days, and the most frequent symptom was pericarditic chest pain (83%). Respectively, 50 and 33% of patients presented after the second and the third dose of the vaccine. Almost all patients were treated with both nonsteroidal anti-inflammatory drugs and colchicine. Five patients (21%) experienced a recurrence of pericarditis. No patient died or developed constrictive pericarditis. Mean follow-up was 8.0 ± 3.2 months. Conclusion: COVID-19 vaccine-related pericarditis typically manifest with mild clinical signs, in young male individuals, a few days after the second or third vaccine dose and are commonly characterized by a rapid complete recovery.

Published
2022

27. B-PO01-091 PREDICTORS OF CONCEALED MYOCARDIAL SCAR ON CARDIAC MAGNETIC RESONANCE IN PATIENTS WITH APPARENTLY IDIOPATHIC VENTRICULAR ARRHYTHMIAS: THE ALARM RISK SCORE

Author

Muser, Daniele, primary, Magnani, Silvia, additional, Nucifora, Gaetano, additional, Enriquez, Andres, additional, Pieroni, Maurizio, additional, Castro, Simon A., additional, Casado Arroyo, Ruben, additional, Shingo, Maeda, additional, Maeda, Shingo, additional, Benhayon, Daniel, additional, Liuba, Ioan, additional, Sadek, Mouhannad, additional, Garcia, Fermin C., additional, Callans, David J., additional, Frankel, David S., additional, Selvanayagam, Joseph, additional, Collini, Valentino, additional, Arkles, Jeffrey, additional, Lin, David, additional, Schaller, Robert D., additional, Tschabrunn, Cory M., additional, Zado, Erica S., additional, Marchlinski, Francis E., additional, and Santangeli, Pasquale, additional

Published
2021
Full Text
View/download PDF

28. B-PO01-079 INCREMENTAL PROGNOSTIC VALUE OF MYOCARDIAL DEFORMATION IN PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY: A FEATURE-TRACKING CARDIAC MAGNETIC RESONANCE STUDY

Author

Muser, Daniele, primary, Magnani, Silvia, additional, Nucifora, Gaetano, additional, Pieroni, Maurizio, additional, Enriquez, Andres, additional, Castro, Simon A., additional, Garcia, Fermin C., additional, Callans, David J., additional, Frankel, David S., additional, Selvanayagam, Joseph, additional, Collini, Valentino, additional, Arkles, Jeffrey, additional, Lin, David, additional, Schaller, Robert D., additional, Zado, Erica S., additional, Tschabrunn, Cory M., additional, Marchlinski, Francis E., additional, and Santangeli, Pasquale, additional

Published
2021
Full Text
View/download PDF

29. Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19

Author

Nuzzi, Vincenzo, primary, Castrichini, Matteo, additional, Collini, Valentino, additional, Roman-Pognuz, Erik, additional, Di Bella, Stefano, additional, Luzzati, Roberto, additional, Berlot, Giorgio, additional, Confalonieri, Marco, additional, Merlo, Marco, additional, Stolfo, Davide, additional, and Sinagra, Gianfranco, additional

Published
2021
Full Text
View/download PDF

30. Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19

Author

Matteo Castrichini, Gianfranco Sinagra, Valentino Collini, Vincenzo Nuzzi, Erik Roman-Pognuz, Davide Stolfo, Marco Merlo, Stefano Di Bella, Giorgio Berlot, Roberto Luzzati, Marco Confalonieri, Nuzzi, Vincenzo, Castrichini, Matteo, Collini, Valentino, ROMAN-POGNUZ, Erik, DI BELLA, Stefano, Luzzati, Roberto, Berlot, Giorgio, Confalonieri, Marco, Merlo, Marco, Stolfo, Davide, and Sinagra, Gianfranco

Subjects
Male, medicine.medical_specialty, 2019-20 coronavirus outbreak, hypertension, Longitudinal strain, Coronavirus disease 2019 (COVID-19), pulmonary, Hypertension, Pulmonary, hypertension, pulmonary, Comorbidity, Internal medicine, Epidemiology, Pandemic, echocardiography, Medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, Pandemics, business.industry, SARS-CoV-2, COVID-19, Middle Aged, medicine.disease, Pulmonary hypertension, Myocardial Contraction, prognosis, right ventricular function, Cardiology, Ventricular Function, Right, Female, Cardiology and Cardiovascular Medicine, business, prognosi
Abstract

Right ventricular (RV) dysfunction (RVD) is associated with worse outcome in coronavirus disease 2019 (COVID-19). Pulmonary hypertension (PH) is a cause of RVD in COVID-19 respiratory failure and is associated with negative prognosis. Major pulmonary embolism, alveolar and endothelial injury, and thrombotic microangiopathy are potential triggers for new-onset PH in the acute phase. Persistent RV involvement has been reported in patients recovered from COVID-19. However, the association between persistent RV impairment and new-onset PH remains unexplored. We evaluated the prevalence of PH and RVD in patients recovered from COVID-19.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results